Dopamine Transporter Imaging with [123I]-beta-CIT Demonstrates Presynaptic Nigrostriatal Dopaminergic Damage in Wilson's Disease

Overview

Journal J Neurol Neurosurg Psychiatry

Publisher BMJ Publishing Group

Specialties Neurology
Neurosurgery
Psychiatry

Date 1998 Jul 17

PMID 9667562

Citations 22

Authors

B Jeon

J M Kim

J M Jeong

K M Kim

Y S Chang

D S Lee

M C Lee

Affiliations

Soon will be listed here.

Abstract

Objectives: The most common neurological manifestations in Wilson's disease are parkinsonism and dystonia. These are assumed to be due to striatal injury, which has been repeatedly demonstrated by pathology and CT or MRI. The substantia nigra has not been shown to be damaged in pathological studies. However, there have been clinical and imaging studies suggesting presynaptic nigrostriatal injury. (1r)-2Beta-carbomethoxy-3beta-(4-iodophenyl)tropane (beta-CIT) is a specific ligand that binds to the dopamine transporter (DAT), and can examine the integrity of dopaminergic nerve terminals. Evidence for presynaptic nigrostriatal dopaminergic damage in Wilson's disease was searched for using [123I]-beta-CIT SPECT.

Methods: Six patients with Wilson's disease were studied, together with 15 healthy normal controls, and six patients with Parkinson's disease. After injection of [123I]-beta-CIT, SPECT studies were done at 18 hours. Specific striatal/occipital binding ratio (S/O ratio) was calculated as (striatal binding-occipital binding)/occipital binding.

Results: The specific S/O ratios were 6.22 (1.32) (mean (SD)) in normal volunteers, 3.78 (0.65) in Parkinson's disease, and 3.60 (0.49) in Wilson's disease.

Conclusion: There was severe loss of the DAT in the striatum suggesting significant damage in presynaptic nigrostriatal dopaminergic nerve terminals. Therefore, a presynaptic lesion may contribute to neurological manifestations in Wilson's disease.

Citing Articles

Copper Overload Increased Rat Striatal Levels of Both Dopamine and Its Main Metabolite Homovanillic Acid in Extracellular Fluid.

Cruces-Sande A, Garrido-Gil P, Sierra-Paredes G, Vazquez-Agra N, Hermida-Ameijeiras A, Pose-Reino A Int J Mol Sci. 2024; 25(15).

PMID: 39125878 PMC: 11312188. DOI: 10.3390/ijms25158309.

Defining Parkinson's Disease: Past and Future.

Kulcsarova K, Skorvanek M, Postuma R, Berg D J Parkinsons Dis. 2024; 14(s2):S257-S271.

PMID: 38489197 PMC: 11492139. DOI: 10.3233/JPD-230411.

Distribution of non-ceruloplasmin-bound copper after i.v. Cu injection studied with PET/CT in patients with Wilson disease.

Munk D, Holm Vendelbo M, Teicher Kirk F, Rewitz K, Bender D, Vase K JHEP Rep. 2023; 5(11):100916.

PMID: 37886434 PMC: 10597763. DOI: 10.1016/j.jhepr.2023.100916.

Decoding Neurodegeneration: A Comprehensive Review of Molecular Mechanisms, Genetic Influences, and Therapeutic Innovations.

Voicu V, Tataru C, Toader C, Covache-Busuioc R, Glavan L, Bratu B Int J Mol Sci. 2023; 24(16).

PMID: 37629187 PMC: 10455143. DOI: 10.3390/ijms241613006.

[Nuclear medicine diagnostics in Wilson's disease].

Hermann W, Hesse S Nervenarzt. 2022; 94(4):327-334.

PMID: 36149458 DOI: 10.1007/s00115-022-01390-3.

References

Barbeau A, Friesen H . Treatment of Wilson's disease with L-dopa after failure with penicillamine. Lancet. 1970; 1(7657):1180-1. DOI: 10.1016/s0140-6736(70)91259-6. View

Morgan J, Preziosi T, BIANCHINE J . Ineffectiveness of L-dopa as supplement to penicillamine in a case of Wilson's disease. Lancet. 1970; 2(7674):659. DOI: 10.1016/s0140-6736(70)91422-4. View

Schwarcz R, Hokfelt T, Fuxe K, Jonsson G, Goldstein M, Terenius L . Ibotenic acid-induced neuronal degeneration: a morphological and neurochemical study. Exp Brain Res. 1979; 37(2):199-216. DOI: 10.1007/BF00237708. View

Kendall B, Pollock S, Bass N, Valentine A . Wilson's disease. Clinical correction with cranial computed tomography. Neuroradiology. 1981; 22(1):1-5. DOI: 10.1007/BF00344602. View

Williams F, Walshe J . Wilson's disease. An analysis of the cranial computerized tomographic appearances found in 60 patients and the changes in response to treatment with chelating agents. Brain. 1981; 104(Pt 4):735-52. DOI: 10.1093/brain/104.4.735. View

Nyberg P, Gottfries C, Holmgren G, Persson S, ROOS B, Winblad B . Advanced catecholaminergic disturbances in the brain in a case of Wilson's disease. Acta Neurol Scand. 1982; 65(1):71-5. DOI: 10.1111/j.1600-0404.1982.tb03063.x. View

Schwarcz R, Whetsell Jr W, Mangano R . Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983; 219(4582):316-8. DOI: 10.1126/science.6849138. View

Aisen A, MARTEL W, Gabrielsen T, Glazer G, Brewer G, Young A . Wilson disease of the brain: MR imaging. Radiology. 1985; 157(1):137-41. DOI: 10.1148/radiology.157.1.4034959. View

Yuh W, Flickinger F . Unusual MR findings in CNS Wilson disease. AJR Am J Roentgenol. 1988; 151(4):834. DOI: 10.2214/ajr.151.4.834-a. View

10.

Prayer L, Wimberger D, Kramer J, Grimm G, Oder W, Imhof H . Cranial MRI in Wilson's disease. Neuroradiology. 1990; 32(3):211-4. DOI: 10.1007/BF00589114. View

11.

Snow B, Bhatt M, Martin W, Li D, Calne D . The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. J Neurol Neurosurg Psychiatry. 1991; 54(1):12-7. PMC: 1014291. DOI: 10.1136/jnnp.54.1.12. View

12.

Burke R, Kent J, Kenyon N, KARANAS A . Unilateral hypoxic-ischemic injury in neonatal rat results in a persistent increase in the density of striatal tyrosine hydroxylase immunoperoxidase staining. Brain Res Dev Brain Res. 1991; 58(2):171-9. DOI: 10.1016/0165-3806(91)90003-2. View

13.

Przedborski S, Kostic V, Jackson-Lewis V, Cadet J, Burke R . Effect of unilateral perinatal hypoxic-ischemic brain injury in the rat on dopamine D1 and D2 receptors and uptake sites: a quantitative autoradiographic study. J Neurochem. 1991; 57(6):1951-61. DOI: 10.1111/j.1471-4159.1991.tb06409.x. View

14.

Burke R, Reches A . Preserved striatal tyrosine hydroxylase activity, assessed in vivo, following neonatal hypoxia-ischemia. Brain Res Dev Brain Res. 1991; 61(2):277-80. DOI: 10.1016/0165-3806(91)90143-7. View

15.

Uhl G . Neurotransmitter transporters (plus): a promising new gene family. Trends Neurosci. 1992; 15(7):265-8. DOI: 10.1016/0166-2236(92)90068-j. View

16.

Kilbourn M, Sherman P, Pisani T . Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol. 1992; 216(1):109-12. DOI: 10.1016/0014-2999(92)90216-q. View

17.

Oertel W, Tatsch K, Schwarz J, Kraft E, Trenkwalder C, Scherer J . Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease. Ann Neurol. 1992; 32(6):743-8. DOI: 10.1002/ana.410320607. View

18.

Laruelle M, Baldwin R, Malison R, Zea-Ponce Y, Zoghbi S, Sybirska E . SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993; 13(4):295-309. DOI: 10.1002/syn.890130402. View

19.

Wilson J, Nobrega J, Carroll M, Niznik H, Shannak K, Lac S . Heterogeneous subregional binding patterns of 3H-WIN 35,428 and 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration. J Neurosci. 1994; 14(5 Pt 2):2966-79. PMC: 6577478. View

20.

Roh J, Lee T, Wie B, Lee S, Park S, Chang K . Initial and follow-up brain MRI findings and correlation with the clinical course in Wilson's disease. Neurology. 1994; 44(6):1064-8. DOI: 10.1212/wnl.44.6.1064. View